Clinical trials: Allergic Rhinoconjunctivitis
Hypersensitivity, Allergic Rhinitis
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing…
- Conditions
- Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis, Seasonal Allergy
- Trial name
- NCT01731249
- Testing
- Birch pollen allergen extract
- Where
- 11 sites in Czechia, Denmark and 9 more
- Volunteers
- 574 people
- Sponsor
- Stallergenes Greer
Allergic Asthma, Allergic Rhinoconjunctivitis
Andosan in Allergic and Asthma Patients
Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with asthma and allergy, undergoing allergen specific immunotherapy experience clinical and biochemical improvement in their…
- Conditions
- Allergic Asthma, Allergic Rhinoconjunctivitis, Immune Tolerance
- Trial name
- NCT05192720
- Testing
- Andosan
- Where
- Norway
- Volunteers
- 34 people
- Sponsor
- University Hospital, Akershus
Hay Fever
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM
gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this clinical trial is to confirm the safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM…
- Trial name
- NCT02156791
- Testing
- gpASIT+TM
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- BioTech Tools S.A.
Rhinoconjunctivitis Due to Grass Pollen Allergy
A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy
Allergen specific immunotherapy (SIT) is the only causative treatment of IgE-mediated allergies. The disadvantages of SIT, however, are the requirement of numerous allergen administrations over three to five years, and that the…
- Trial name
- NCT00470457
- Testing
- Allergen specific immunotherapy
- Where
- Switzerland
- Volunteers
- 156 people
- Sponsor
- University of Zurich
Allergic Rhinoconjunctivitis
Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis
The purpose of ths study is to evaluate changes in life quality of patients affected by rhinoconjuntivitis with or without asthma after immunotherapy treatment.
- Trial name
- ÍCARA (NCT02488447)
- Where
- 14 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Roxall Medicina España S.A
Cat Allergy, Rhinoconjunctivitis
An Optional Two Year Follow Up Study to Study CP005A
Cat allergy is an increasingly prevalent condition affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01604018
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Circassia Limited
Seasonal Allergic Rhinitis
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
The objective of this study is to assess the effect of grass pollen extract SLIT tablets on the Rhinoconjunctivitis Total Symptom Score (RTSS) of the six rhinoconjunctivitis symptoms in response to grass pollen challenge after…
- Trial name
- NCT00619827
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Austria
- Volunteers
- 89 people
- Sponsor
- Stallergenes Greer
Rhinitis, Rhinoconjunctivitis
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
This is an open-label, non-controlled, non-randomised, prospective safety study in patients with rhinitis or allergic rhinoconjunctivitis, with controlled asthma, and clinically relevant sensitisation to dust mites from the…
- Conditions
- Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- NCT02340130
- Testing
- DP/MG/14-1, DP/MG/14-2
- Where
- 3 sites in Spain
- Volunteers
- 57 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy, Rhinitis
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.
- Conditions
- Allergy, Rhinitis, Rhinoconjunctivitis, Seasonal Asthma
- Trial name
- NCT01734265
- Testing
- Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml), Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy, Rhinitis
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Efficacy and Safety from a high-dosed sublingual grass pollen preparation
- Conditions
- Allergy, Rhinitis, Conjunctivitis
- Trial name
- ALLEGRA6 (NCT00623701)
- Testing
- Allerslit forte
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Phleum pratense in the rhinoconjunctivitis and/or asthma of slight or moderate…
- Conditions
- Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic, Asthma
- Trial name
- NCT00501527
- Testing
- Immunotherapy with modified extract of P. pratense pollen
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Laboratorios Leti, S.L.
Seasonal Allergic Rhinitis
Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber
The purpose of this study is to determine whether Ragweed-SPIRE is safe and effective at reducing allergy symptoms in people who suffer from allergy to Ragweed pollen
- Trial name
- NCT02061709
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 280 people
- Sponsor
- Circassia Limited
Perennial Allergy to House Dust Mite and/or Cat
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.
- Trial name
- NCT00575003
- Testing
- CYT003-QbG10
- Where
- 7 sites in Estonia, Latvia and 1 more
- Volunteers
- 64 people
- Sponsor
- Cytos Biotechnology AG
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH
Allergic Rhinitis, Allergic Asthma
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic…
- Conditions
- Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite
- Trial name
- MM09-SLIM (NCT05641272)
- Testing
- 3,000 MM09, 9,000 MM09
- Where
- Argentina
- Volunteers
- 90 people
- Sponsor
- Inmunotek S.L.
Birch Pollen Allergy
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd…
- Trial name
- NCT02143583
- Where
- 22 sites in Denmark, France and 5 more
- Volunteers
- 196 people
- Sponsor
- Anergis
Allergy
Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis
Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans and animals, including asthma, allergic rhinitis, conjunctivitis and dermatitis.
- Trial name
- NCT01166061
- Testing
- ToleroMune Grass
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Circassia Limited
Grass Pollen Allergy
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
The trial is performed to assess efficacy and safety of the Grass Pollen Allergoid in Allergic Rhinoconjunctivitis
- Trial name
- NCT00263601
- Testing
- Allergovit 6-grasses
- Where
- Germany
- Volunteers
- 154 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis
Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study
TX-SMILE is an investigator-initiated, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intra-lymphatic administration of an approved…
- Conditions
- Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
- Trial name
- TX-SMILE (NCT03682965)
- Testing
- Intra-lymphatic allergenic extract
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Christopher Thompson, MD
Birch Pollen Allergy
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
- Trial name
- NCT00309062
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG